Mark Yarchoan is an Associate Professor of Medical Oncology at Johns Hopkins with NCI-funded research in immunotherapy development, particularly cancer vaccines. He has conducted clinical trials of immunotherapy agents including neoantigen-targeted approaches.
Intro paths
YC
Mark went through Y Combinator (Winter 2023) — any YC alum in your network can reach them through the YC community.
GP
Their group partner at YC was Tom Blomfield, General Partner at Y Combinator — the partner who ran Adventris Pharmaceuticals's batch and knows the company first-hand. YC profile ↗
→
In turn, Mark can intro founders to Adventris Pharmaceuticals's investors below.
Adventris Pharmaceuticals's investors · 3
Co-founders
JH
Jen HerbachFounder
WC
William CollisFounder